羟基喜树碱冻干粉针+顺铂腹腔化疗联合TACE在中晚期肝癌中的临床应用  

10-hydroxycamptothecinc plus cisplatin intraperitoneal chemotherapy combined with TACE for advanced liver cancer

作　　者：黄锡梅[1] 苏炳光[1] 蔡茂德[1] 凌华晃[1] 

机构地区：[1]高州市人民医院肿瘤化疗科,广东高州525200

出　　处：《现代肿瘤医学》2008年第8期1372-1374,共3页Journal of Modern Oncology

摘　　要：目的:评价羟基喜树碱冻干粉针(HCPT)+顺铂(DDP)腹腔灌注联合肝动脉栓塞化疗术(TACE)在中晚期肝癌患者中的临床疗效。方法:肝癌患者按住院先后随机分为:治疗组48例:腹腔化疗:HCPT30mg+DDP60mg,第二天行TACE;对照组45例:采用单纯TACE治疗。两方案均是每50天1周期,每例至少化疗2周期。结果:治疗组总有效率62.5%,生活质量改善率72.92%,AFP下降率70.0%,中位生存期11.5个月。对照组总有效率31.11%,生活质量改善率35.56%,AFP下降率34.21%,中位生存期8.2个月,两组比较,差异有显著性(P<0.05)。结论:羟基喜树碱冻干粉针+顺铂腹腔化疗联合TACE对中晚期肝癌患者是一种安全、有效的治疗方法。Objective： To evaluate the clinical effect of 10 -hydroxycamptothecinc plus cisplatin intraperitoneal chemotherapy combined with transcatheter arterial chemoembolization （TACE） for advanced liver cancer. Methods： Ninety -three patients with advanced liver cancer were divided into two groups： Treatment group , 48 patients received intraperitoneal chemoembolization： HCPT 30mg ＋ DDP 60mg,TACE on day 2. Control group, 45 patients received TACE only. All chemotherapy cycles were repeated every 50 days, all patients received at least two cycles. Results： In the treatment group ： the overall response rate was 62.5 %, the quality of life improvement rate was 72. 92% ,the AFP reduction rate was 70.0% ,the median survival time was 11.5 months. In the control group ： the overall response rate was 31.11% ,the quality of life improvement rate was 35.56 % ,the AFP reduction rate was 34.21 % , the median survival time was 8.2 months. The difference of the two groups was significant （ P 〈 0.05 ）. Conclu- sion： 10- hydroxycamptothecinc plus cisplatin intraperitoneal chemotherapy combined with TACE is safe and effective for advanced liver cancer.

关 键 词：羟基喜树碱 顺铂 化疗 TACE 肝癌 

分 类 号：R735.2[医药卫生—肿瘤]